Kollipara Naga Venkata Chenchu Lakshmi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kollipara Naga Venkata Chenchu Lakshmi has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Shaik Aminabee
V.V. Institute of Pharmaceutical Sciences, Gudlavalleru, India
8 shared publications - K. Ravi Shankar
KVSR Siddhartha College of Pharmaceutical Sciences
4 shared publications - Aziz Unnisa
Department of Pharmaceutical Chemistry, College of Pharmacy , University of Hail , Hail , Saudi Arabia
3 shared publications A S Abouzied
2 shared publicationsB Anupama
2 shared publicationsHariharan Thirumalai Vengateswaran
Crescent School of Pharmacy, B.S. Abdur Rahman Crescent Institute of Science and Technology
2 shared publications
Latest Publications
- 26 September 2026
- Published by Wiley in Separation Science Plus
- Vol. 9 (9) , e70313
Box–Behnken Optimized Reversed‐Phase Ultra‐High‐Performance Liquid Chromatography Method for Simultaneous Trace‐Level Determination of Process‐Related Impurities in Sunitinib Drug Substance
An RP‐UHPLC method was developed for the simultaneous trace‐level quantification of three process‐related impurities of sunitinib malate: sunitinib amide impurity (IMP‐1), sunitinib carboxylic acid impurity (IMP‐2), and 5‐fluoroindolin‐2‐one (IMP‐3). Systematic optimization proceeded through a three‐factor Box–Behnken design evaluating acetonitrile content (40%–60% v/v), mobile phase pH (3.5–4.5), and column temperature (30°C–40°C) across 17 randomized experimental runs; quadratic polynomial models for all three responses—sunitinib retention time, Rs(IMP‐1/IMP‐2), and Rs(IMP‐2/sunitinib)—yielded R 2 ≥ 0.9997, adjusted R 2 ≥ 0.9993, and nonsignificant lack‐of‐fit in every case ( p ≥ 0.05). Numerical optimization via composite desirability maximization ( D = 0.750) identified 50% acetonitrile in 10 mM ammonium formate (pH 3.8) at 35°C as the operating optimum, affording baseline resolution of all four analytes in 6 min on an Agilent Poroshell 120 EC‐C18 column (2.1 × 100 mm, 1.9 µm). Validation followed the ICH Q2(R2) framework for a Category II quantitative impurity test, and the numbers held up well: linearity across 5–150 ng mL −1 with r ≥ 0.999; LOQ values between 8.48 and 16.97 ng mL −1 (a six‐ to twelvefold margin under the 0.1% specification threshold); accuracy of 98.9%–100.4%; and combined precision with %RSD no higher than 1.03%.
- 26 September 2026
- Published by Wiley in Separation Science Plus
- Vol. 9 (9) , e70313
Box–Behnken Optimized Reversed‐Phase Ultra‐High‐Performance Liquid Chromatography Method for Simultaneous Trace‐Level Determination of Process‐Related Impurities in Sunitinib Drug Substance
An RP‐UHPLC method was developed for the simultaneous trace‐level quantification of three process‐related impurities of sunitinib malate: sunitinib amide impurity (IMP‐1), sunitinib carboxylic acid impurity (IMP‐2), and 5‐fluoroindolin‐2‐one (IMP‐3). Systematic optimization proceeded through a three‐factor Box–Behnken design evaluating acetonitrile content (40%–60% v/v), mobile phase pH (3.5–4.5), and column temperature (30°C–40°C) across 17 randomized experimental runs; quadratic polynomial models for all three responses—sunitinib retention time, Rs(IMP‐1/IMP‐2), and Rs(IMP‐2/sunitinib)—yielded R 2 ≥ 0.9997, adjusted R 2 ≥ 0.9993, and nonsignificant lack‐of‐fit in every case ( p ≥ 0.05). Numerical optimization via composite desirability maximization ( D = 0.750) identified 50% acetonitrile in 10 mM ammonium formate (pH 3.8) at 35°C as the operating optimum, affording baseline resolution of all four analytes in 6 min on an Agilent Poroshell 120 EC‐C18 column (2.1 × 100 mm, 1.9 µm). Validation followed the ICH Q2(R2) framework for a Category II quantitative impurity test, and the numbers held up well: linearity across 5–150 ng mL −1 with r ≥ 0.999; LOQ values between 8.48 and 16.97 ng mL −1 (a six‐ to twelvefold margin under the 0.1% specification threshold); accuracy of 98.9%–100.4%; and combined precision with %RSD no higher than 1.03%.
- Open Access
- 30 June 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 1451-1462
Herbal Modulators of JAK/STAT Signalling in Chronic Inflammatory and Autoimmune Disorders: An Integrative Approach
Background: Janus kinase/signal transducer and activator of transcription (JAK/STAT) is a key signaling protocol operating in the regulation of immune cells, cytokine communication and inflammation. The JAK/STAT pathway has been implicated in the pathogenesis of several chronic inflammatory and autoimmune diseases, including Rheumatoid Arthritis (RA), psoriasis, Inflammatory Bowel Disease (IBD), and Systemic Lupus Erythematosus (SLE). While pharmacological JAK inhibitors (e.g., tofacitinib, ruxolitinib) have shown therapeutic efficacy, their long-term use is often limited by adverse effects, high costs, and immunosuppressive risks. Over the last few years, a growing body of evidence has highlighted the potential of herbal formulations and plant-derived bioactive compounds as safe, effective, and multi-target modulators of the JAK/STAT pathway. Phytochemicals (curcumin, resveratrol, berberine, and andrographolide) have been observed to affect key actors of this pathway (by inhibiting JAK kinases, STAT activation, and upstream proinflammatory cytokines downregulation). Aim: The aim is to systematically explore the molecular mechanisms of herbal modulators acting on JAK/STAT signalling, their relevance in disease-specific contexts, and the evidence from preclinical and clinical studies. The review dwells on the new methods that are being developed to comprehend the polypharmacological aspect of such compounds, such as network pharmacology, systems biology, and molecular docking. Result: Integrating herbal therapeutics into JAK/STAT-targeted strategies offers a promising complementary approach to conventional therapies. Nevertheless, more clinical research and standardisation of the composition, as well as safety profiling, are required to confirm their usage in treatment. Conclusion: The present integrative review will inform future research, which would aim at the utilisation of herbal bioactives in the chronic inflammatory and autoimmune disease management using JAK/STAT modulation. Major Findings: The modulation of JAK/STAT signalling pathway by inhibiting JAK phosphorylation, suppressing the expression of pro-inflammatory cytokines and regulating the activation of STAT occurs with herbal compounds containing curcumin, withaferin A and berberine, which suppress pro-inflammatory cytokines and modulate JAK/STAT signalling pathway in autoimmune and inflammatory disorders. In spite of positive data in preclinical studies, M-T effect and even despite multi-targeting effects of their therapeutic properties, standardised clinical trials and also pharmacokinetic studies should be continued to integrate them into the repertoire of mainstream immunotherapies.
- 30 June 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 1451-1462
Open AccessHerbal Modulators of JAK/STAT Signalling in Chronic Inflammatory and Autoimmune Disorders: An Integrative Approach
Background: Janus kinase/signal transducer and activator of transcription (JAK/STAT) is a key signaling protocol operating in the regulation of immune cells, cytokine communication and inflammation. The JAK/STAT pathway has been implicated in the pathogenesis of several chronic inflammatory and autoimmune diseases, including Rheumatoid Arthritis (RA), psoriasis, Inflammatory Bowel Disease (IBD), and Systemic Lupus Erythematosus (SLE). While pharmacological JAK inhibitors (e.g., tofacitinib, ruxolitinib) have shown therapeutic efficacy, their long-term use is often limited by adverse effects, high costs, and immunosuppressive risks. Over the last few years, a growing body of evidence has highlighted the potential of herbal formulations and plant-derived bioactive compounds as safe, effective, and multi-target modulators of the JAK/STAT pathway. Phytochemicals (curcumin, resveratrol, berberine, and andrographolide) have been observed to affect key actors of this pathway (by inhibiting JAK kinases, STAT activation, and upstream proinflammatory cytokines downregulation). Aim: The aim is to systematically explore the molecular mechanisms of herbal modulators acting on JAK/STAT signalling, their relevance in disease-specific contexts, and the evidence from preclinical and clinical studies. The review dwells on the new methods that are being developed to comprehend the polypharmacological aspect of such compounds, such as network pharmacology, systems biology, and molecular docking. Result: Integrating herbal therapeutics into JAK/STAT-targeted strategies offers a promising complementary approach to conventional therapies. Nevertheless, more clinical research and standardisation of the composition, as well as safety profiling, are required to confirm their usage in treatment. Conclusion: The present integrative review will inform future research, which would aim at the utilisation of herbal bioactives in the chronic inflammatory and autoimmune disease management using JAK/STAT modulation. Major Findings: The modulation of JAK/STAT signalling pathway by inhibiting JAK phosphorylation, suppressing the expression of pro-inflammatory cytokines and regulating the activation of STAT occurs with herbal compounds containing curcumin, withaferin A and berberine, which suppress pro-inflammatory cytokines and modulate JAK/STAT signalling pathway in autoimmune and inflammatory disorders. In spite of positive data in preclinical studies, M-T effect and even despite multi-targeting effects of their therapeutic properties, standardised clinical trials and also pharmacokinetic studies should be continued to integrate them into the repertoire of mainstream immunotherapies.
- Open Access
- 30 March 2026
- Published by Oriental Scientific Publishing Company in Biosciences Biotechnology Research Asia
- Vol. 1 (23) , 1-16
Smart Nanobiotechnological Platforms for Gene and Drug Delivery: From Biopolymers to Pharmaceutical Applications
Smart nanobiotechnological platforms have become a solace of revolution in conquering the challenges linked to the traditional drug and gene delivery system. The platforms allow targeted, stimuli-responsive, and precise delivery of therapeutic agents by incorporating the benefits of nanotechnology, biotechnology, and pharmaceutical sciences. The biocompatibility, biodegradability and versatility of biopolymers have been vital in designing smart nanocarriers since the biopolymers can be used to efficiently encapsulate drugs and genetic materials and release them on demand. The given review will be a complete overview of the application of smart nanobiotechnological platforms in gene and drug delivery with a particular emphasis on the key principles of the design, nanocarrier biopolymers, and stimuli responsiveness. They are particularly stressed in relation to their use in gene therapy, cancer therapy, neurology, and infectious diseases. The review further talks of pharmacokinetic and pharmacodynamic factors, safety and toxicity issues, and regulatory issues that arise with nanobiomaterials. The latest developments, such as the AI-assisted nanocarrier design and individualized nanomedicine are also discussed. In general, this review highlights the promise of smart nanobiotechnological platforms, which can transform the concept of delivering therapeutic interventions and speed up the process of translating nanomedicine into clinical care.
- 30 March 2026
- Published by Oriental Scientific Publishing Company in Biosciences Biotechnology Research Asia
- Vol. 1 (23) , 1-16
Open AccessSmart Nanobiotechnological Platforms for Gene and Drug Delivery: From Biopolymers to Pharmaceutical Applications
Smart nanobiotechnological platforms have become a solace of revolution in conquering the challenges linked to the traditional drug and gene delivery system. The platforms allow targeted, stimuli-responsive, and precise delivery of therapeutic agents by incorporating the benefits of nanotechnology, biotechnology, and pharmaceutical sciences. The biocompatibility, biodegradability and versatility of biopolymers have been vital in designing smart nanocarriers since the biopolymers can be used to efficiently encapsulate drugs and genetic materials and release them on demand. The given review will be a complete overview of the application of smart nanobiotechnological platforms in gene and drug delivery with a particular emphasis on the key principles of the design, nanocarrier biopolymers, and stimuli responsiveness. They are particularly stressed in relation to their use in gene therapy, cancer therapy, neurology, and infectious diseases. The review further talks of pharmacokinetic and pharmacodynamic factors, safety and toxicity issues, and regulatory issues that arise with nanobiomaterials. The latest developments, such as the AI-assisted nanocarrier design and individualized nanomedicine are also discussed. In general, this review highlights the promise of smart nanobiotechnological platforms, which can transform the concept of delivering therapeutic interventions and speed up the process of translating nanomedicine into clinical care.
- 9 March 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 479
Targeting the extracellular matrix in precision medicine: opportunities for diagnostics and therapeutics
- 9 March 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 479
Targeting the extracellular matrix in precision medicine: opportunities for diagnostics and therapeutics
- 10 January 2026
- Published by Springer Nature
- p. 583-601
Revolutionizing Drug Delivery: The Role of Artificial Intelligence in Nanomedicine and Precision Pharma
- 10 January 2026
- Published by Springer Nature
- p. 583-601
Revolutionizing Drug Delivery: The Role of Artificial Intelligence in Nanomedicine and Precision Pharma
- Open Access
- 1 January 2026
- Published by Wolters Kluwer Health in Asian Journal of Pharmaceutical Research and Health Care
- Vol. 18 (1) , 46-52
Reverse-phase High-performance Liquid Chromatography: High-performance Liquid Chromatography Method Used for Estimating Cefuroxime Axetil in Tablet and Bulk Dosage Formulations
A BSTRACT: Background: Cefuroxime axetil, an effective second-generation cephalosporin antibiotic, requires valid analytical technique for bulk medication and tablet quality control. Aim and Objective: The current study developed a speedy, efficient, accurate, and cost-effective RP-HPLC (Reverse Phase High Performance Liquid Chromatography) technology that has been developed and validated for the quantification of Cefuroxime axetil in bulk and pharmaceutical formulations using a C8 column. Materials and Methods: The chromatography method employed a Base Deactivated Silica(BDS)-Hyperil C8 column (250 × 4.6 mm, 5 microns) with a mobile phase of acetonitrile and water at a 55:45 v/v ratio, at a flow rate of 1.025 ml/min. The method supports green principles was analyzed using a Shimadzu-LC-20AT HPLC system at a wavelength of 277 nm. The approach was assessed in accordance with ICH(International Council for Harmonisation) criteria. Results and Discussion: The results indicated the trustworthiness of the marketed formulation (cefakind 500 mg), with a purity of 99.09%. The retention time of Cefuroxime Axetil was 4.349 ± 0.02 minutes, with a correlation value ( R ²) of 0.9998, demonstrating excellent linearity within the 30-70 µg/mL range. The limits of detection (LOD) and quantification (LOQ) were 0.0180 µg/ml and 0.0546 µg/ml, respectively. The average recovery was 99.09%, guaranteeing exceptional precision. The approach demonstrated accuracy (% RSD = 0.06) and robustness against minor fluctuations in analytical conditions. The suggested RP-HPLC method is straightforward, swift, precise, accurate, and cost-effective, rendering it appropriate for regular quality control, dissolution analysis, and bioequivalence assessment of Cefuroxime axetil in pharmaceutical formulations.
- 1 January 2026
- Published by Wolters Kluwer Health in Asian Journal of Pharmaceutical Research and Health Care
- Vol. 18 (1) , 46-52
Open AccessReverse-phase High-performance Liquid Chromatography: High-performance Liquid Chromatography Method Used for Estimating Cefuroxime Axetil in Tablet and Bulk Dosage Formulations
A BSTRACT: Background: Cefuroxime axetil, an effective second-generation cephalosporin antibiotic, requires valid analytical technique for bulk medication and tablet quality control. Aim and Objective: The current study developed a speedy, efficient, accurate, and cost-effective RP-HPLC (Reverse Phase High Performance Liquid Chromatography) technology that has been developed and validated for the quantification of Cefuroxime axetil in bulk and pharmaceutical formulations using a C8 column. Materials and Methods: The chromatography method employed a Base Deactivated Silica(BDS)-Hyperil C8 column (250 × 4.6 mm, 5 microns) with a mobile phase of acetonitrile and water at a 55:45 v/v ratio, at a flow rate of 1.025 ml/min. The method supports green principles was analyzed using a Shimadzu-LC-20AT HPLC system at a wavelength of 277 nm. The approach was assessed in accordance with ICH(International Council for Harmonisation) criteria. Results and Discussion: The results indicated the trustworthiness of the marketed formulation (cefakind 500 mg), with a purity of 99.09%. The retention time of Cefuroxime Axetil was 4.349 ± 0.02 minutes, with a correlation value ( R ²) of 0.9998, demonstrating excellent linearity within the 30-70 µg/mL range. The limits of detection (LOD) and quantification (LOQ) were 0.0180 µg/ml and 0.0546 µg/ml, respectively. The average recovery was 99.09%, guaranteeing exceptional precision. The approach demonstrated accuracy (% RSD = 0.06) and robustness against minor fluctuations in analytical conditions. The suggested RP-HPLC method is straightforward, swift, precise, accurate, and cost-effective, rendering it appropriate for regular quality control, dissolution analysis, and bioequivalence assessment of Cefuroxime axetil in pharmaceutical formulations.
- Open Access
- 31 December 2025
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 2815-2828
Plant-based Adaptogens in Stress Management: Traditional Use and Modern Evidence
The assault of stress has developed into one of the biggest health issues in the world, a condition that has led to a large variety of both psychological and physiological imbalances. In this regard, herbal adaptogens, i.e., a type of natural compounds that increase the ability of the body to keep itself resistant to the pressures of stress, provide an interesting, comprehensive solution to stress management. This review explores the traditional foundations and modern pharmacological evidence supporting the use of adaptogenic medicinal plants.Based on ancient traditions like Ayurveda, Traditional Chinese Medicine (TCM), and native ethnomedicine, we point out the most important adaptogenic herbs, Withania somnifera (Ashwagandha), Panax ginseng, Rhodiola rosea, Ocimum sanctum (Tulsi) and Bacopa monnieri (Brahmi). Their phytoconstituents,such as withanolides, ginsenosides, rosavins, and bacosides,are shown to exert neuroprotective, anti-inflammatory, antioxidant, and endocrine-modulating effects, particularly through regulation of the Hypothalamic-Pituitary-Adrenal (HPA) axis and stress-related biomarkers. The review combines the outcome of preclinical and clinical studies, which show substantial threats in the mitigation of anxiety, fatigue, and enhancement of stress cognitive performance. The improvement of the delivery systems and formulation technology, including nanoformulations and phytosomes to increase bioavailability and therapeutic efficiency,is also covered. Additionally, issues of standardisation, safety, and regulatory frameworks are examined to ensure the rational use of adaptogens in integrative healthcare.This review connects the information of the previous century and before regarding the question about plant-based adaptogens and potential therapeutic uses in preventing and treating conditions caused by stress, and heralds the ways to implement them in future studies and practice. Major Findings: Traditional solutions to stress, plant-based adaptogens have scientifically confirmed stress-protective, neuroendocrine, and antioxidant properties, whereas they are potentially promising in integrative therapy, and their overall research and regulatory development are expected to focus on their standardisation, long-term safety, and clinical trial needs.
- 31 December 2025
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 2815-2828
Open AccessPlant-based Adaptogens in Stress Management: Traditional Use and Modern Evidence
The assault of stress has developed into one of the biggest health issues in the world, a condition that has led to a large variety of both psychological and physiological imbalances. In this regard, herbal adaptogens, i.e., a type of natural compounds that increase the ability of the body to keep itself resistant to the pressures of stress, provide an interesting, comprehensive solution to stress management. This review explores the traditional foundations and modern pharmacological evidence supporting the use of adaptogenic medicinal plants.Based on ancient traditions like Ayurveda, Traditional Chinese Medicine (TCM), and native ethnomedicine, we point out the most important adaptogenic herbs, Withania somnifera (Ashwagandha), Panax ginseng, Rhodiola rosea, Ocimum sanctum (Tulsi) and Bacopa monnieri (Brahmi). Their phytoconstituents,such as withanolides, ginsenosides, rosavins, and bacosides,are shown to exert neuroprotective, anti-inflammatory, antioxidant, and endocrine-modulating effects, particularly through regulation of the Hypothalamic-Pituitary-Adrenal (HPA) axis and stress-related biomarkers. The review combines the outcome of preclinical and clinical studies, which show substantial threats in the mitigation of anxiety, fatigue, and enhancement of stress cognitive performance. The improvement of the delivery systems and formulation technology, including nanoformulations and phytosomes to increase bioavailability and therapeutic efficiency,is also covered. Additionally, issues of standardisation, safety, and regulatory frameworks are examined to ensure the rational use of adaptogens in integrative healthcare.This review connects the information of the previous century and before regarding the question about plant-based adaptogens and potential therapeutic uses in preventing and treating conditions caused by stress, and heralds the ways to implement them in future studies and practice. Major Findings: Traditional solutions to stress, plant-based adaptogens have scientifically confirmed stress-protective, neuroendocrine, and antioxidant properties, whereas they are potentially promising in integrative therapy, and their overall research and regulatory development are expected to focus on their standardisation, long-term safety, and clinical trial needs.
- Open Access
- 30 December 2025
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 4 (18) , 2985
Comprehensive Analysis of Saussurea lappa: GC-MS Profiling, In Silico Evaluation, Toxicity Prediction, and Molecular Docking for Breast Cancer Therapy
The study's purpose is to conduct a thorough analysis of the Saussurea lappa root extract. The research focused on primary screening for phytochemicals followed by GC-MS analysis of both polar and non-polar extracts. A total of 34 components were found in the root extract; 1, 8-cyclopentadecadiyne was found to have the highest percentage in both extracts. The findings from SWISS target prediction, the PASS online database, and pdCSM-cancer are corroborated by the examination of structure-based biological activities, demonstrating that the anticancer capabilities of this plant root chemical are derived from structure-based drug advancements. The in-silico outcomes showed interactions involving alkyl bonds, binding affinity with EGFR kinase inhibitors, anti-proliferative proteins, and Steroid DELTA-isomerize target proteins were determined. A computational synergistic study was also performed to predict the possible drug combinations that can be administered with Saussurea lappa to treat cancer. This suggests an increased potential for developing anticancer drugs to treat breast cancer.
- 30 December 2025
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 4 (18) , 2985
Open AccessComprehensive Analysis of Saussurea lappa: GC-MS Profiling, In Silico Evaluation, Toxicity Prediction, and Molecular Docking for Breast Cancer Therapy
The study's purpose is to conduct a thorough analysis of the Saussurea lappa root extract. The research focused on primary screening for phytochemicals followed by GC-MS analysis of both polar and non-polar extracts. A total of 34 components were found in the root extract; 1, 8-cyclopentadecadiyne was found to have the highest percentage in both extracts. The findings from SWISS target prediction, the PASS online database, and pdCSM-cancer are corroborated by the examination of structure-based biological activities, demonstrating that the anticancer capabilities of this plant root chemical are derived from structure-based drug advancements. The in-silico outcomes showed interactions involving alkyl bonds, binding affinity with EGFR kinase inhibitors, anti-proliferative proteins, and Steroid DELTA-isomerize target proteins were determined. A computational synergistic study was also performed to predict the possible drug combinations that can be administered with Saussurea lappa to treat cancer. This suggests an increased potential for developing anticancer drugs to treat breast cancer.
- 10 July 2025
- Published by Taylor & Francis
- p. 264-296
Conclusion and Future Prospects on Drug Discovery
In this chapter, we summarize recent progress in drug discovery and assess its implications for future research and development. The final section summarizes recent key findings from high-throughput screening (HTS), biomarker identification and personalized medicine. Moreover, it identifies the challenges encountered, like high costs, extended development cycles and both regulatory and commercial hurdles. Emerging trends in drug discovery, such as artificial intelligence (AI), genomic integration, and new therapeutic modalities, are explored as future prospects. By highlighting the successes, the challenges that persist, and the innovations that might alter the face of drug development, this analysis covers the full version of the progress to date. Results highlight a need for sustained interdisciplinary partnerships and continued investment in state-of-the-art technologies to overcome current constraints and progress discovery toward new, effective therapies.
- 10 July 2025
- Published by Taylor & Francis
- p. 264-296
Conclusion and Future Prospects on Drug Discovery
In this chapter, we summarize recent progress in drug discovery and assess its implications for future research and development. The final section summarizes recent key findings from high-throughput screening (HTS), biomarker identification and personalized medicine. Moreover, it identifies the challenges encountered, like high costs, extended development cycles and both regulatory and commercial hurdles. Emerging trends in drug discovery, such as artificial intelligence (AI), genomic integration, and new therapeutic modalities, are explored as future prospects. By highlighting the successes, the challenges that persist, and the innovations that might alter the face of drug development, this analysis covers the full version of the progress to date. Results highlight a need for sustained interdisciplinary partnerships and continued investment in state-of-the-art technologies to overcome current constraints and progress discovery toward new, effective therapies.